论文部分内容阅读
目的 :研究古拉定 (还原型谷胱甘肽 )防治头颈部肿瘤放疗所致口腔粘膜、放射反应的临床效果及不良反应。方法 :从放疗第 3周起 ,随机分为治疗组 (古拉定 ) 4 0例及对照组 (口泰 ) 39例 ,按WHO粘膜反应 0～ 4级标准 ,观察口腔粘膜反应及药物不良反应。结果 :第 4周两组疗效对比无明显差异 (P >0 .0 5 ) ,第 7周古拉定组3～ 4级反应明显少于口泰组 ,差异显著 (P <0 .0 5 ) ,无明显药物不良反应。结论 :古拉定可作为头颈部肿瘤放疗的辅助治疗药物
Objective: To study the clinical effect and adverse reactions of Guladine (reduced glutathione) in the prevention and treatment of oral mucosa caused by radiotherapy of head and neck cancer. Methods: From the third week of radiotherapy, the patients were randomly divided into treatment group (GOP) 40 cases and control group (Cotai group) 39 cases. The oral mucosal reaction and adverse drug reaction . Results: There was no significant difference between the two groups in the 4th week (P> 0.05). The level 3 to 4 of the Gladladin group in the 7th week was significantly lower than that in the Koutai group (P <0.05) , No obvious adverse drug reactions. Conclusion: Guladin can be used as head and neck cancer radiotherapy adjuvant therapy